keyword
MENU ▼
Read by QxMD icon Read
search

Sofosbuvir

keyword
https://www.readbyqxmd.com/read/28632109/successful-treatment-of-sexually-acquired-acute-hcv-reinfection-with-ledipasvir-sofosbuvir-in-a-hiv-infected-patient
#1
Salvatore Sollima, Spinello Antinori, Alessandro Torre, Francesca Binda, Andrea Giacomelli, Laura Milazzo
Here we describe the case of a HIV-positive patient with acute hepatitis C virus reinfection, who was successfully treated with an interferon-free regimen of ledipasvir/sofosbuvir.
July 2017: International Journal of STD & AIDS
https://www.readbyqxmd.com/read/28627403/accepting-hearts-from-hepatitis-c-positive-donor-can-we-expand-the-donor-pool
#2
Jonathan Grinstein, Laura M Lourenco, Helen S Te, John F Renz, Valluvan Jeevanandam, Nir Uriel
BACKGROUND: Until recently, transplantation from hepatitis C positive donors was relatively contraindicated as eradication of active hepatitis C previously required an interferon-based regimen which has been associated with rejection in solid organ transplantation. New interferon-free treatment regimens for hepatitis C have fewer adverse events and higher cure rates than interferon-based regimens. Interferon-free regimens have been shown to be safe in the liver transplantation literature but little is known about the safety and efficacy of treatment in heart transplantation...
June 13, 2017: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/28622881/discovery-of-%C3%AE-d-2-deoxy-2-dichlorouridine-nucleotide-prodrugs-as-potent-inhibitors-of-hepatitis-c-virus-replication
#3
Pedro Pinho, Genadiy Kalayanov, Hans Westerlind, Åsa Rosenquist, Horst Wähling, Christian Sund, Maria Almeida, Susana Ayesa, Jan Tejbrant, Paul Targett-Adams, Anders Eneroth, Annelie Lindqvist
Discovery of sofosbuvir has radically changed hepatitis C treatment and nucleoside/tide NS5B inhibitors are now viewed as one of the key components in combination therapies with other direct-acting antiviral agents. As part of our program to identify new nucleoside inhibitors of HCV replication, we now wish to report on the discovery of β-d-2'-deoxy-2'-dichlorouridine nucleotide prodrugs as potent inhibitors of HCV replication. Although, cytidine analogues have long been recognized to be metabolized to both cytidine and uridine triphosphates through the action of cytidine deaminase, uridine analogues are generally believed to produce exclusively uridine triphosphate...
May 26, 2017: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/28619439/origin-prevalence-and-response-to-therapy-of-hepatitis-c-virus-genotype-2k-1b-chimeras
#4
Simone Susser, Julia Dietz, Bernhard Schlevogt, Eli Zuckerman, Mira Barak, Valeria Piazzolla, Anita Howe, Holger Hinrichsen, Sandra Passmann, Rasha Daniel, Markus Cornberg, Alessandra Mangia, Stefan Zeuzem, Christoph Sarrazin
BACKGROUND & AIMS: Little is known about the epidemiology and frequency of recombinant HCV genotype 2/1 strains which may represent a challenge for direct antiviral therapy (DAA). METHODS: Consecutive samples from HCV genotype 2 infected patients from Germany, Italy and Israel according to commercial genotyping were re-genotyped by Sanger-based sequencing. Virologic, epidemiological, and phylogenetic analyses including other published chimeras were performed. RESULTS: Sequence analysis of 442 supposed HCV genotype 2 isolates revealed 61 (genotype 2k/1b (n=59), 2a/1b (n=1) or 2b/1a (n=1)) chimeras...
June 12, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28619394/understanding-real-world-adherence-in-the-directly-acting-antiviral-era-a-prospective-evaluation-of-adherence-among-people-with-a-history-of-drug-use-at-a-community-based-program-in-toronto-canada
#5
Kate Mason, Zoë Dodd, Mary Guyton, Paula Tookey, Bernadette Lettner, John Matelski, Sanjeev Sockalingam, Jason Altenberg, Jeff Powis
BACKGROUND: Direct acting antiviral (DAA) treatments for Hepatitis C (HCV) are now widely available with sustained virologic response (SVR) rates of >90%. A major predictor of response to DAAs is adherence, yet few real-world studies evaluating adherence among marginalized people who use drugs and/or alcohol exist. This study evaluates patterns and factors associated with non-adherence among marginalized people with a history of drug use who were receiving care through a primary care, community-based HCV treatment program where opiate substitution is not offered on-site...
June 12, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28618285/belgian-experience-with-direct-acting-antivirals-in-people-who-inject-drugs
#6
Rob Bielen, Christophe Moreno, Hans Van Vlierberghe, Stefan Bourgeois, Jean-Pierre Mulkay, Thomas Vanwolleghem, Wim Verlinden, Christian Brixko, Jochen Decaestecker, Chantal De Galocsy, Filip Janssens, Mike Cool, Lode Van Overbeke, Christophe Van Steenkiste, François D'heygere, Wilfried Cools, Frederik Nevens, Geert Robaeys
BACKGROUND AND AIM: Hepatitis C viral infection (HCV) has become a curable disease due to the development of direct acting antivirals (DAA). The WHO has set a target to eliminate HCV completely. Therefore, people who inject drugs (PWID) also need to be treated. In this study, we compared the real-life uptake and outcome of DAA treatment for HCV in PWID and non-PWID. METHODS: We performed a nation-wide, retrospective cohort study in 15 hospitals. All patients who were treated with simeprevir-sofosbuvir, daclatasvir-sofosbuvir, or ombitasvir/paritaprevir ritonavir-dasabuvir between December 2013 and November 2015 were included...
May 30, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28618152/potential-risk-of-hbv-reactivation-in-patients-with-resolved-hbv-infection-undergoing-direct-acting-antiviral-treatment-for-hcv
#7
Eiichi Ogawa, Norihiro Furusyo, Masayuki Murata, Kazuhiro Toyoda, Takeo Hayashi, Kazuya Ura
BACKGROUND AND AIMS: Despite a known risk of hepatitis B virus (HBV) reactivation during direct-acting antiviral (DAA) treatment for patients with hepatitis C virus (HCV)-HBV coinfection, it remains unclear whether patients with past HBV infection are at risk for reactivation. This study evaluated the risk of HBV reactivation during treatment with sofosbuvir (SOF)-based regimens, focusing on patients with resolved HBV infection. METHODS: This study analyzes the data of 183 consecutive patients treated with SOF-based regimens...
June 15, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28615303/favouring-modulation-of-circulating-lipoproteins-and-lipid-loading-capacity-by-direct-antiviral-agents-grazoprevir-elbasvir-or-ledipasvir-sofosbuvir-treatment-against-chronic-hcv-infection
#8
Hung-Yu Sun, Pin-Nan Cheng, Chiung-Ying Tseng, Wei-Jen Tsai, Yen-Cheng Chiu, Kung-Chia Young
OBJECTIVE: Lipid homoeostasis is disturbed in patients with HCV infection. Direct-acting antiviral agent (DAA) treatment eradicates chronic HCV viraemia, but the dynamics of lipid components remain elusive. This study investigates the clinical manifestation and mechanistic relevance of plasma triglyceride (TG), cholesterol (Chol), lipoproteins and apolipoproteins (apos) after DAA treatment. DESIGN: Twenty-four patients with chronic genotype 1 (GT1) HCV treated with elbasvir/grazoprevir or ledipasvir/sofosbuvir for 12 weeks, and followed-up thereafter, were recruited...
June 14, 2017: Gut
https://www.readbyqxmd.com/read/28608973/high-hepatitis-c-cure-rates-among-black-and-non-black-hiv-infected-adults-in-an-urban-center
#9
Oluwaseun Falade-Nwulia, Catherine Sutcliffe, Juhi Moon, Geetanjali Chander, Tanyaporn Wansom, Jeanne Keruly, Jennifer Katzianer, Amy Nathanson, Jillian Marks, Shruti Mehta, David Thomas, Richard Moore, Mark Sulkowski
Background Hepatitis C virus (HCV) cure rates have been similar in patients with and without HIV co-infection; however, in the ION-4 study, black patients treated with ledipasvir/sofosbuvir were significantly less likely to achieve cure (90%) compared to non-black patients (99%). There are limited real world data on the effectiveness of oral direct acting antivirals (DAAs) in predominantly minority HIV/HCV co-infected populations. Methods We analyzed HCV treatment outcomes among 255 HCV co-infected patients initiating DAAs between February 2014 and March 2016 in an urban clinic in Baltimore, Maryland...
June 13, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28596225/increased-warfarin-requirements-in-a-patient-with-chronic-hepatitis-c-infection-receiving-sofosbuvir-and-ribavirin
#10
Daisy Peterson, Amy Van Ermen
PURPOSE: A case of increased warfarin requirements during treatment with sofosbuvir and ribavirin for chronic hepatitis C virus (HCV) infection is reported. SUMMARY: A 63-year-old white man receiving long-term anticoagulation with warfarin for atrial fibrillation and a history of cardioembolic stroke was initiated in September 2014 on a 12-week course of sofosbuvir 400 mg orally daily and weight-based ribavirin 600 mg orally twice daily for HCV genotype 2 infection...
June 15, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28595606/detection-of-a-genetic-footprint-of-the-sofosbuvir-resistance-associated-substitution-s282t-after-hcv-treatment-failure
#11
Andreas Walker, Sandra Filke, Nadine Lübke, Martin Obermeier, Rolf Kaiser, Dieter Häussinger, Jörg Timm, Hans H Bock
BACKGROUND: The major resistance-associated substitution for sofosbuvir (S282T) in HCV NS5B causes severe viral fitness costs and rapidly reverts back to prototype in the absence of selection pressure. Accordingly, resistance against sofosbuvir is rarely detected even in patients after treatment failure. CASE PRESENTATION: We report a case of a GT3a infected patient with viral breakthrough under SOF/DCV therapy. At the time of breakthrough the RAS S282T was predominant in NS5B and then rapidly disappeared during follow-up by week 12 after treatment...
June 8, 2017: Virology Journal
https://www.readbyqxmd.com/read/28585416/implications-of-hcv-rna-level-at-week-4-of-direct-antiviral-treatments-for-hepatitis-c
#12
Kay Johnson, Pamela K Green, George N Ioannou
We aimed to determine whether the HCV viral load after four weeks of treatment (W4VL) with direct-acting antiviral agents (DAAs) predicts sustained virologic response (SVR) in a real-world clinical setting. We identified 21,095 patients who initiated DAA-based antiviral treatment in the national Veterans Affairs (VA) healthcare system from 01/01/2014 to 06/30/2015. Week 4 viral load was categorized as undetectable, detectable below quantification, detectable above quantification with viral load ≤42 IU/mL and detectable above quantification with viral load > 42 IU/mL...
June 5, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28585404/frequency-of-and-factors-associated-with-hepatitis-b-virus-reactivation-in-hepatitis-c-patients-treated-with-all-oral-direct-acting-antivirals-analysis-of-a-japanese-prospective-cohort
#13
Akira Doi, Ryotaro Sakamori, Yuki Tahata, Ayako Urabe, Naoki Morishita, Ryoko Yamada, Kunimaro Furuta, Takahiro Kodama, Hayato Hikita, Takayuki Yakushijin, Kazuyoshi Ohkawa, Akira Kaneko, Yasuharu Imai, Tomohide Tatsumi, Tetsuo Takehara
AIM: Several case reports have shown that hepatitis B virus (HBV) reactivation developed in hepatitis C patients with a current or previous HBV infection during direct-acting antiviral (DAA) treatment, which led to severe hepatitis or death in some cases. However, its precise frequency and risk factors are not entirely clear. We analyzed a prospective cohort. METHODS: We analyzed HBV reactivation in 461 consecutive hepatitis C patients who received 12 weeks of ledipasvir/sofosbuvir for genotype 1 or sofosbuvir plus ribavirin for genotype 2 at multiple centers...
June 5, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28584851/successful-pre-and-posttransplant-sofosbuvir-based-anti-hepatitis-c-virus-treatment-in-persons-living-with-human-immunodeficiency-virus-infection
#14
Giovanni Guaraldi, Roberto Rossotti, Gabriella Verucchi, Marcello Tavio, Luisa Pasulo, Barbara Beghetto, Giovanni Dolci, Giulia Nardini, Lorenzo Badia, Anna Magliano, Maria Cristina Moioli, Massimo Puoti
This retrospective study reports the data of sofosbuvir-based anti-hepatitis C virus treatment in 24 candidates and 24 recipients of liver transplantation coinfected with human immunodeficiency virus. Sustained virologic response was cumulatively 85% (90% and 100% in those treated with optimal schedules pre- and posttransplant, respectively).
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28581634/no-one-size-fits-all-shortening-duration-of-therapy-with-direct-acting-antivirals-for-hepatitis-c-genotype-1-infection
#15
Omar El Sherif, Nezam Afhdal, Michael Curry
The advent of shorter duration, highly effective and well tolerated interferon-free therapy now provides an opportunity for virtually all HCV infected individuals to be cured. However, there continues to be a need to simplify and shorten treatment duration. Shortening therapy to 8 weeks with sofosbuvir and ledipasvir can be considered in treatment patients with HCV genotype 1 infection and low baseline viral load. A number of other 8 week dual and triple therapy direct acting antiviral (DAA) regimens are in advanced clinical development...
June 5, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28564569/sofosbuvir-velpatasvir-and-voxilaprevir-for-previously-treated-hcv-infection
#16
RANDOMIZED CONTROLLED TRIAL
Marc Bourlière, Stuart C Gordon, Steven L Flamm, Curtis L Cooper, Alnoor Ramji, Myron Tong, Natarajan Ravendhran, John M Vierling, Tram T Tran, Stephen Pianko, Meena B Bansal, Victor de Lédinghen, Robert H Hyland, Luisa M Stamm, Hadas Dvory-Sobol, Evguenia Svarovskaia, Jie Zhang, K C Huang, G Mani Subramanian, Diana M Brainard, John G McHutchison, Elizabeth C Verna, Peter Buggisch, Charles S Landis, Ziad H Younes, Michael P Curry, Simone I Strasser, Eugene R Schiff, K Rajender Reddy, Michael P Manns, Kris V Kowdley, Stefan Zeuzem
BACKGROUND: Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options. METHODS: We conducted two phase 3 trials involving patients who had been previously treated with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1 infection who had previously received a regimen containing an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive either the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor voxilaprevir (150 patients) or matching placebo (150 patients) once daily for 12 weeks...
June 1, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28554119/effectiveness-and-safety-of-ledipasvir-sofosbuvir%C3%A2-ribavirin-in-the-treatment-of-hcv-infection-the-real-world-harvest-study
#17
Robert Flisiak, Mariusz Łucejko, Włodzimierz Mazur, Ewa Janczewska, Hanna Berak, Krzysztof Tomasiewicz, Iwona Mozer-Lisewska, Dorota Kozielewicz, Andrzej Gietka, Katarzyna Sikorska, Marta Wawrzynowicz-Syczewska, Krzysztof Nowak, Dorota Zarębska-Michaluk, Joanna Musialik, Krzysztof Simon, Aleksander Garlicki, Robert Pleśniak, Barbara Baka-Ćwierz, Iwona Olszok, Krystyna Augustyniak, Wojciech Stolarz, Jolanta Białkowska, Anna Badurek, Anna Piekarska
BACKGROUND: To evaluate the effectiveness and safety of ledipasvir/sofosbuvir (LDV/SOF)±ribavirin (RBV) regimen in a real-world setting. METHODS: Patients received a fixed-dose combination tablet containing LDV and SOF with or without RBV, for 8, 12 or 24 weeks. Patients were assessed at baseline, end of treatment, and 12 weeks after the end of treatment. The primary effectiveness endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12)...
May 26, 2017: Advances in Medical Sciences
https://www.readbyqxmd.com/read/28552102/advances-in-research-on-zika-virus
#18
REVIEW
Amjad Ali, Braira Wahid, Shazia Rafique, Muhammad Idrees
Zika virus (ZIKV) is rapidly spreading across the America and its devastating outcomes for pregnant women and infants have driven this previously ignored pathogen into the limelight. Clinical manifestations are fever, joint pain or rash and conjunctivitis. Emergence of ZIKV started with a first outbreak in the Pacific area in 2007, a second large outbreak occurred in the Pacific in 2013/2014 and subsequently the virus spread in other Pacific islands. Threat of explosive global pandemic and severe clinical complications linked with the more immediate and recurrent epidemics necessitate the development of an effective vaccine...
April 2017: Asian Pacific Journal of Tropical Medicine
https://www.readbyqxmd.com/read/28545127/improvement-of-alt-decay-kinetics-by-all-oral-hcv-treatment-role-of-ns5a-inhibitors-and-differences-with-ifn-based-regimens
#19
Valeria Cento, Thi Huyen Tram Nguyen, Domenico Di Carlo, Elisa Biliotti, Laura Gianserra, Ilaria Lenci, Daniele Di Paolo, Vincenza Calvaruso, Elisabetta Teti, Maddalena Cerrone, Dante Romagnoli, Michela Melis, Elena Danieli, Barbara Menzaghi, Ennio Polilli, Massimo Siciliano, Laura Ambra Nicolini, Antonio Di Biagio, Carlo Federico Magni, Matteo Bolis, Francesco Paolo Antonucci, Velia Chiara Di Maio, Roberta Alfieri, Loredana Sarmati, Paolo Casalino, Sergio Bernardini, Valeria Micheli, Giuliano Rizzardini, Giustino Parruti, Tiziana Quirino, Massimo Puoti, Sergio Babudieri, Antonella D'Arminio Monforte, Massimo Andreoni, Antonio Craxì, Mario Angelico, Caterina Pasquazzi, Gloria Taliani, Jeremie Guedj, Carlo Federico Perno, Francesca Ceccherini-Silberstein
BACKGROUND: Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-used all-DAA combinations to evaluate their mode of action and cytotoxicity compared with telaprevir (TVR)+PR. STUDY DESIGN: Mathematical modeling of ALT and HCV-RNA kinetics was performed in 111 HCV-1 cirrhotic patients, 81 treated with all-DAA regimens and 30 with TVR+PR...
2017: PloS One
https://www.readbyqxmd.com/read/28543053/sofosbuvir-and-ribavirin-in-adolescents-12-to-17-years-old-with-hepatitis-c-virus-genotype-2-or-3-infection
#20
Stefan Wirth, Philip Rosenthal, Regino P Gonzalez-Peralta, Maureen M Jonas, William F Balistreri, Lin Chuan-Hao, Winita Hardikar, Kathryn Kersey, Benedetta Massetto, Bittoo Kanwar, Diana M Brainard, Jiang Shao, Evguenia Svarovskaia, Brian Kirby, Ronen Arnon, Karen F Murray, Kathleen B Schwarz
BACKGROUND & AIMS: Children with chronic hepatitis C virus (HCV) infection have limited treatment options. We evaluated the all-oral combination of sofosbuvir and ribavirin in adolescents aged 12-17 with HCV genotype 2 or 3. METHODS: Fifty-two patients received sofosbuvir 400mg once daily and weight-based ribavirin twice daily for 12 (genotype 2) or 24 (genotype 3) weeks. The pharmacokinetics of sofosbuvir and its metabolite GS-331007 were evaluated by intensive plasma sampling at day 7 in the first 10 patients enrolled, and by sparse sampling in all patients throughout treatment...
May 22, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
keyword
keyword
9774
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"